Triple therapy for advanced liver cancer with bile duct invasion
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer that has spread into the bile ducts and cannot be removed with surgery.
- You haven't had any cancer treatment (like chemotherapy, immunotherapy, or targeted drugs) for this cancer before.
- You have at least one tumor that can be seen on a CT or MRI scan and is at least 1 cm across.
- You are well enough to be up and about (ECOG 0 or 1), have good liver function (Child-Pugh A or B), and your blood counts are normal enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.